Related references
Note: Only part of the references are listed.Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy
Tung-Hung Su et al.
JOURNAL OF GASTROENTEROLOGY (2014)
HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Jia-Horng Kao
LIVER INTERNATIONAL (2014)
HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
Wai-Kay Seto et al.
CLINICAL INFECTIOUS DISEASES (2013)
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
Pietro Lampertico et al.
GUT (2013)
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B
Pietro Lampertico et al.
HEPATOLOGY (2013)
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads
Tai-Chung Tseng et al.
HEPATOLOGY (2013)
Immediate Intraportal Transplantation of Human Bone Marrow Mesenchymal Stem Cells Prevents Death From Fulminant Hepatic Failure in Pigs
Tao Wei et al.
HEPATOLOGY (2013)
Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
Milan J. Sonneveld et al.
HEPATOLOGY (2013)
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
Hung-Chih Yang et al.
HEPATOLOGY (2013)
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Patrick Marcellin et al.
HEPATOLOGY INTERNATIONAL (2013)
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α
Jacinta A. Holmes et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT
C. -J. Liu et al.
JOURNAL OF HEPATOLOGY (2013)
Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers
Tai-Chung Tseng et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma
De-Ke Jiang et al.
NATURE GENETICS (2013)
Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
Huei-Ru Cheng et al.
PLOS ONE (2013)
Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese
Xiaopan Wu et al.
ANTIVIRAL RESEARCH (2012)
High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load
Tai-Chung Tseng et al.
GASTROENTEROLOGY (2012)
Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B
Milan J. Sonneveld et al.
GASTROENTEROLOGY (2012)
New perspectives in the therapy of chronic hepatitis B
Pietro Lampertico et al.
GUT (2012)
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
Tai-Chung Tseng et al.
HEPATOLOGY (2012)
Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development
Lingmin Hu et al.
HEPATOLOGY (2012)
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
Milan J. Sonneveld et al.
HEPATOLOGY (2012)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2012)
Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections: Case-control study and meta-analysis
Zehui Yan et al.
INFECTION GENETICS AND EVOLUTION (2012)
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
Vincent Rijckborst et al.
JOURNAL OF HEPATOLOGY (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters
Tai-Chung Tseng et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation
Tai-Chung Tseng et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers
Johannes Vermehren et al.
PLOS ONE (2012)
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy
Tai-Chung Tseng et al.
ANTIVIRAL THERAPY (2011)
Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters
Tai-Chung Tseng et al.
GASTROENTEROLOGY (2011)
Further Analysis Is Required to Identify an Early Stopping Rule for Peginterferon Therapy That Is Valid for All Hepatitis B e Antigen-Positive Patients
Teerha Piratvisuth et al.
HEPATOLOGY (2011)
Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C
Y. -F. Liaw et al.
HEPATOLOGY (2011)
Strong Influence of Human Leukocyte Antigen (HLA)-DP Gene Variants on Development of Persistent Chronic Hepatitis B Virus Carriers in the Han Chinese Population
Xiuchan Guo et al.
HEPATOLOGY (2011)
A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese
Ping An et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B
Jurrien G. P. Reijnders et al.
GASTROENTEROLOGY (2010)
Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-up Study
Jessica Liu et al.
GASTROENTEROLOGY (2010)
Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers
Maurizia Rossana Brunetto et al.
GASTROENTEROLOGY (2010)
Early On-Treatment Prediction of Response to Peginterferon Alfa-2a for HBeAg-Negative Chronic Hepatitis B Using HBsAg and HBV DNA Levels
Vincent Rijckborst et al.
HEPATOLOGY (2010)
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen Positive Chronic Hepatitis B Using On-Treatment Hepatitis B Surface Antigen Decline
Milan J. Sonneveld et al.
HEPATOLOGY (2010)
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers
Hongxing Zhang et al.
NATURE GENETICS (2010)
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2009)
Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a
Patrick Marcellin et al.
GASTROENTEROLOGY (2009)
Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients
Rami Moucari et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B
Pisit Tangkijvanich et al.
JOURNAL OF CLINICAL VIROLOGY (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians
Yoichiro Kamatani et al.
NATURE GENETICS (2009)
Hepatitis B virus variants
Watcharasak Chotiyaputta et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2008)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Michael W. Fried et al.
HEPATOLOGY (2008)
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
Hwai-I Yang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Role of viral factors in the natural course and therapy of chronic hepatitis B
Jia-Horng Kao
HEPATOLOGY INTERNATIONAL (2007)
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response
Henry Lik-Yuen Chan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
Genotype B and younger patient age associated with better response to low-dose therapy:: A trial with pegylated/nonpegylated interferon-α-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China
Hong Zhao et al.
CLINICAL INFECTIOUS DISEASES (2007)
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B:: A randomized study
CJ Liu et al.
HEPATOLOGY (2006)
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
UH Iloeje et al.
GASTROENTEROLOGY (2006)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Response to interferon alfa is hepatitis B virus genotype dependent:: genotype A is more sensitive to interferon than genotype D
A Erhardt et al.
GUT (2005)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS)
S Foser et al.
PROTEIN EXPRESSION AND PURIFICATION (2003)
Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
WGE Cooksley et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers
JH Kao et al.
GASTROENTEROLOGY (2003)
Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan
JH Kao
INTERVIROLOGY (2003)
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications
YS Wang et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Pegylation - A novel process for modifying pharmacokinetics
JM Harris et al.
CLINICAL PHARMACOKINETICS (2001)
Hepatitis B genotypes and the response to interferon therapy
JH Kao et al.
JOURNAL OF HEPATOLOGY (2000)
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
A Erhardt et al.
HEPATOLOGY (2000)
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
JH Kao et al.
GASTROENTEROLOGY (2000)
Share Paper
